{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:30:27Z","timestamp":1791559827327,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320 .6750.2022-09-19"],"award-info":[{"award-number":["320 .6750.2022-09-19"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Fund of China","doi-asserted-by":"crossref","award":["81872400"],"award-info":[{"award-number":["81872400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Key Research and Development Program of Shandong","award":["2021SFGC0501"],"award-info":[{"award-number":["2021SFGC0501"]}]},{"name":"Joint Innovation and Development Item of Shandong Natural Scientific Fund","award":["ZR2021LZL008"],"award-info":[{"award-number":["ZR2021LZL008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14250-5","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T10:43:29Z","timestamp":1746614609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Kugeluke","family":"Yalikun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuetao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"3","key":"14250_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"14250_CR2","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555\u201367. https:\/\/doi.org\/10.1016\/S2214-109X(18)30127-X.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"14250_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"14250_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label,\u00a0phase II. Trial Clin Cancer Res. 2021;27(4):1003\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2571.","journal-title":"Trial Clin Cancer Res"},{"issue":"10408","key":"14250_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(23)00961-3.","journal-title":"Lancet."},{"issue":"3","key":"14250_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jvir.2018.09.004","volume":"30","author":"N Lyu","year":"2019","unstructured":"Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread. J Vasc Interv Radiol. 2019;30(3):349-357.e2. https:\/\/doi.org\/10.1016\/j.jvir.2018.09.004.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"14250_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953\u201360. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0250.","journal-title":"JAMA Oncol"},{"issue":"11","key":"14250_CR8","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1097\/JS9.0000000000000654","volume":"109","author":"M Deng","year":"2023","unstructured":"Deng M, Cai H, He B, Guan R, Lee C, Guo R. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. Int J Surg. 2023;109(11):3303\u201311. https:\/\/doi.org\/10.1097\/JS9.0000000000000654.","journal-title":"Int J Surg"},{"issue":"2","key":"14250_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.21037\/hbsn-21-328","volume":"11","author":"HC Sun","year":"2022","unstructured":"Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227\u201352. https:\/\/doi.org\/10.21037\/hbsn-21-328.","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"3","key":"14250_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000528356","volume":"12","author":"JY Wu","year":"2022","unstructured":"Wu JY, Zhang ZB, Zhou JY, Ke JP, Bai YN, Chen YF, et al. Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study. Liver Cancer. 2022;12(3):229\u201337. https:\/\/doi.org\/10.1159\/000528356.","journal-title":"Liver Cancer"},{"issue":"5","key":"14250_CR11","doi-asserted-by":"publisher","first-page":"zrac114","DOI":"10.1093\/bjsopen\/zrac114","volume":"6","author":"WF Qu","year":"2022","unstructured":"Qu WF, Ding ZB, Qu XD, Tang Z, Zhu GQ, Fu XT, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 2022;6(5):zrac114. https:\/\/doi.org\/10.1093\/bjsopen\/zrac114.","journal-title":"BJS Open."},{"issue":"385","key":"14250_CR12","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679.","journal-title":"Sci Transl Med."},{"issue":"4","key":"14250_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000514313","volume":"10","author":"XD Zhu","year":"2021","unstructured":"Zhu XD, Huang C, Shen YH, Ji Y, Ge NL, Qu XD, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 2021;10(4):320\u20139. https:\/\/doi.org\/10.1159\/000514313.","journal-title":"Liver Cancer"},{"key":"14250_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/JHC.S332420","volume":"8","author":"JY Wu","year":"2021","unstructured":"Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, et al. Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma. 2021;8:1233\u201340. https:\/\/doi.org\/10.2147\/JHC.S332420.","journal-title":"J Hepatocell Carcinoma"},{"issue":"9","key":"14250_CR15","doi-asserted-by":"publisher","first-page":"e007366","DOI":"10.1136\/jitc-2023-007366","volume":"11","author":"W Zhang","year":"2023","unstructured":"Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J Immunother Cancer. 2023;11(9):e007366. https:\/\/doi.org\/10.1136\/jitc-2023-007366.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"14250_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.004.","journal-title":"J Hepatol"},{"issue":"12","key":"14250_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(12):1025\u201335. https:\/\/doi.org\/10.1016\/S2468-1253(21)00305-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"14250_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117\u201327. https:\/\/doi.org\/10.1200\/JCO.22.00392.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14250_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169\u201378. https:\/\/doi.org\/10.1016\/S2468-1253(22)00339-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"14250_CR20","doi-asserted-by":"publisher","unstructured":"Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, Zheng L, Chen MS, Shi M, Wei W, Guo RP. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:167\u201376. https:\/\/doi.org\/10.2147\/JHC.S298538.","DOI":"10.2147\/JHC.S298538"},{"key":"14250_CR21","doi-asserted-by":"publisher","unstructured":"He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis. Cardiovasc Intervent Radiol. 2018;41(5):734\u201343. https:\/\/doi.org\/10.1007\/s00270-017-1874-z.","DOI":"10.1007\/s00270-017-1874-z"},{"key":"14250_CR22","doi-asserted-by":"publisher","unstructured":"Liu D, Mu H, Liu C, Zhang W, Cui Y, Wu Q, Zhu X, Fang F, Zhang W, Xing W, Li Q, Song T, Lu W, Li H. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial. Neoplasma. 2023;70(6):811\u201318. https:\/\/doi.org\/10.4149\/neo_2023_230806N413.","DOI":"10.4149\/neo_2023_230806N413"},{"key":"14250_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10690-6","author":"M Zuo","year":"2024","unstructured":"Zuo M, Cao Y, Yang Y, Zheng G, Li D, Shao H, et al. Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma. Hepatol Int. 2024. https:\/\/doi.org\/10.1007\/s12072-024-10690-6.","journal-title":"Hepatol Int"},{"issue":"1","key":"14250_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, Wu PH, Gu YK. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023;8(1):413. https:\/\/doi.org\/10.1038\/s41392-023-01663-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"14250_CR25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436\u201343. https:\/\/doi.org\/10.1158\/2326-6066.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"14250_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol Res. 2019;7(4):630\u201343. https:\/\/doi.org\/10.1158\/2326-6066.","journal-title":"Cancer Immunol Res"},{"key":"14250_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","volume":"33","author":"E Lanitis","year":"2015","unstructured":"Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55\u201363. https:\/\/doi.org\/10.1016\/j.coi.2015.01.011.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"14250_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.hpb.2023.03.004","volume":"25","author":"Y Cao","year":"2023","unstructured":"Cao Y, Tang H, Hu B, Zhang W, Wan T, Han J, et al. Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. HPB (Oxford). 2023;25(7):775\u201387. https:\/\/doi.org\/10.1016\/j.hpb.2023.03.004.","journal-title":"HPB (Oxford)"},{"key":"14250_CR29","doi-asserted-by":"publisher","first-page":"913464","DOI":"10.3389\/fimmu.2022.913464","volume":"13","author":"Q Ke","year":"2022","unstructured":"Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of transarterial chemo(Embolization) combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma in the era of systemic therapy: a systematic review. Front Immunol. 2022;13:913464. https:\/\/doi.org\/10.3389\/fimmu.2022.913464.","journal-title":"Front Immunol"},{"issue":"1","key":"14250_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12876-024-03457-8","volume":"24","author":"Z Chang","year":"2024","unstructured":"Chang Z, Li M, Sun Z, Liu Z, Yang Y, Xu L, et al. Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years. BMC Gastroenterol. 2024;24(1):369. https:\/\/doi.org\/10.1186\/s12876-024-03457-8.","journal-title":"BMC Gastroenterol"},{"key":"14250_CR31","doi-asserted-by":"publisher","first-page":"1004652","DOI":"10.3389\/fonc.2022.1004652","volume":"12","author":"L Luo","year":"2022","unstructured":"Luo L, Xiao Y, Zhu G, Huang A, Song S, Wang T, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience. Front Oncol. 2022;12:1004652. https:\/\/doi.org\/10.3389\/fonc.2022.1004652.","journal-title":"Front Oncol"},{"issue":"1","key":"14250_CR32","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Liu J, Zhang B, Yue J, Shi X, Cui K, et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nat Commun. 2024;15(1):3260. https:\/\/doi.org\/10.1038\/s41467-024-47420-3.","journal-title":"Nat Commun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14250-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14250-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14250-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T10:43:30Z","timestamp":1746614610000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14250-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14250"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14250-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent, and the Shandong Cancer Hospital Research Institute Ethics Committee approved the protocol (No. SDZLEC2021-021\u201301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.Z. is on the speakers\u2019 bureau for Bayer, MSD, AstraZeneca, Roche, BeiGene, Innovent, Junshi Biosciences and Jiangsu Hengrui Pharmaceuticals. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"838"}}